Literature DB >> 22198862

Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma.

Kristóf Árvai1, Katalin Nagy, Helga Barti-Juhász, István Peták, Tibor Krenács, Tamás Micsik, Gyula Végső, Ferenc Perner, Béla Szende.   

Abstract

The objective of the study was to examine proliferation and apoptosis associated gene expression in the whole sequence parathyroid lesions to reveal specific features of carcinoma. This study was based on surgically removed parathyroid tissues, gene expression analysis was performed both at gene and protein level. First, mRNA isolation was performed from deep-frozen tissue samples, and further apoptosis pathway-specific cDNA macroarray analysis was carried out. The results were validated with real-time PCR. Subsequently, protein expression was analyzed with immunhistochemistry on Tissue Micro Array multi-blocks derived from several paraffin-embedded samples. cDNA macroarrays revealed elevated expression of both pro-apoptotic (FAS receptor, TRAIL ligand, CASPASE8, and -4) and anti-apoptotic (cIAP1, APOLLON) genes in benign proliferative lesions compared to that in normal gland. TMA studies showed overexpression of KI67, P53, SURVIVIN and APOLLON protein and failure of expression of P27, BCL2, BAX, CHROMOGRANIN-A, SYNAPTOPHYSIN, CYCLIND1, FLIP, TRAIL, CK8, CK18, CK19 in parathyroid carcinoma was detected. These alterations in gene expression of the investigated products could be used in differentiation between beningn and malignant proliferative processes of the parathyroid gland. Authors conclude that a series of alterations in gene expression such as overexpression of APOLLON, P53, KI67 and suppression of P27, BCL2, BAX lead to uncontrolled cell proliferation, but still not leading to increased apoptotic activity in parathyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198862     DOI: 10.1007/s12253-011-9483-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  22 in total

Review 1.  Hyperparathyroid and hypoparathyroid disorders.

Authors:  S J Marx
Journal:  N Engl J Med       Date:  2000-12-21       Impact factor: 91.245

Review 2.  Parathyroid carcinoma: a review of 62 patients.

Authors:  E Shane; J P Bilezikian
Journal:  Endocr Rev       Date:  1982       Impact factor: 19.871

3.  Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.

Authors:  Geoffrey E Woodard; Ling Lin; Jian-Hua Zhang; Sunita K Agarwal; Stephen J Marx; William F Simonds
Journal:  Oncogene       Date:  2005-02-10       Impact factor: 9.867

4.  The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors.

Authors:  M P Vargas; H I Vargas; D E Kleiner; M J Merino
Journal:  Mod Pathol       Date:  1997-01       Impact factor: 7.842

5.  Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype.

Authors:  Carola J Haven; Viive M Howell; Paul H C Eilers; Robert Dunne; Masayuki Takahashi; Marjo van Puijenbroek; Kyle Furge; Job Kievit; Min-Han Tan; Gert Jan Fleuren; Bruce G Robinson; Leigh W Delbridge; Jeanette Philips; Anne E Nelson; Ulf Krause; Henning Dralle; Cuong Hoang-Vu; Oliver Gimm; Hans Morreau; Deborah J Marsh; Bin T Teh
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

6.  Defining a molecular phenotype for benign and malignant parathyroid tumors.

Authors:  Gustavo G Fernandez-Ranvier; Elham Khanafshar; David Tacha; Mariwil Wong; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  Cancer       Date:  2009-01-15       Impact factor: 6.860

7.  Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?

Authors:  Gustavo G Fernandez-Ranvier; Elham Khanafshar; Kristin Jensen; Rasa Zarnegar; James Lee; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  Cancer       Date:  2007-07-15       Impact factor: 6.860

8.  Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.

Authors:  Viive M Howell; Anthony Gill; Adele Clarkson; Anne E Nelson; Robert Dunne; Leigh W Delbridge; Bruce G Robinson; Bin T Teh; Oliver Gimm; Deborah J Marsh
Journal:  J Clin Endocrinol Metab       Date:  2008-11-18       Impact factor: 5.958

9.  Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred.

Authors:  Maurizio Iacobone; Giulia Masi; Luisa Barzon; Andrea Porzionato; Veronica Macchi; Francesco Antonio Ciarleglio; Giorgio Palù; Raffaele De Caro; Giovanni Viel; Gennaro Favia
Journal:  Langenbecks Arch Surg       Date:  2009-06-16       Impact factor: 3.445

10.  Apoptosis and P53, Bcl-2 and Bax gene expression in parathyroid glands of patients with hyperparathyroidism.

Authors:  Béla Szende; Parvaneh Farid; Gyula Végso; Ferenc Perner; László Kopper
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

View more
  8 in total

Review 1.  Immunohistochemistry in Diagnostic Parathyroid Pathology.

Authors:  Lori A Erickson; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

2.  Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms.

Authors:  Angelica M Silva-Figueroa; Roland Bassett; Ioannis Christakis; Pablo Moreno; Callisia N Clarke; Naifa L Busaidy; Elizabeth G Grubbs; Jeffrey E Lee; Nancy D Perrier; Michelle D Williams
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

Review 3.  Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.

Authors:  Romans Uljanovs; Stanislavs Sinkarevs; Boriss Strumfs; Liga Vidusa; Kristine Merkurjeva; Ilze Strumfa
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

4.  Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.

Authors:  Peter P Truran; Sarah J Johnson; Richard D Bliss; Thomas W J Lennard; Sebastian R Aspinall
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

5.  Predictors of multiglandular disease in primary hyperparathyroidism.

Authors:  Mark Thier; Sébastien Daudi; Anders Bergenfelz; Martin Almquist
Journal:  Langenbecks Arch Surg       Date:  2018-01-02       Impact factor: 3.445

6.  Role of Ca²⁺ in Inhibiting Ischemia-Induced Apoptosis of Parathyroid Gland Cells in New Zealand White Rabbits.

Authors:  Wei-Han Cao; Yan-Jun Su; Nian-Qiu Liu; Ying Peng; Chang Diao; Ruo-Chuan Cheng
Journal:  Med Sci Monit       Date:  2020-02-19

7.  Gene expression and methylation profiles show the involvement of POMC in primary hyperparathyroidsm.

Authors:  Wen-Xuan Zhou; Shu Wang; Ting-Chao Wu; Ling-Chao Cheng; Yao Du; Wei Wu; Chen Lin; Xin-Ying Li; Zhong-Liang Hu
Journal:  J Transl Med       Date:  2022-08-16       Impact factor: 8.440

Review 8.  Diagnosis, management, histology and genetics of sporadic primary hyperparathyroidism: old knowledge with new tricks.

Authors:  Maria Mizamtsidi; Constantinos Nastos; George Mastorakos; Roberto Dina; Ioannis Vassiliou; Maria Gazouli; Fausto Palazzo
Journal:  Endocr Connect       Date:  2018-01-12       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.